pharmaphorum

DECEMBER 14, 2022

In order to bring it to market, a special program called Risk Evaluation and Mitigation Strategy (REMS) had to be put in place, where only eligible patients could access the drug through a very strict process. Furthermore, Molina stated Jazz “suppressed generic competition and raised the price of Xyrem 841% between 2007 and 2014.”

Competition 117

Competition FDA Pharmaceutical Marketing 117

pharmaphorum

NOVEMBER 30, 2022

The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine? Founded in 2007 by Peter Gassner, a luminary of Silicon Valley with a net worth of circa $5.25 A 10th anniversary reconnection, reassessment, and race for relevance.

Pharma 98

Pharma Consulting Marketing Sales 98

Pharmaceutical Technology

AUGUST 26, 2008

.” By the early 2000s AstraZeneca had already realised the critical importance of biotechnology, making a number of strategic investments in biotech companies, Abgenix in 2003, Cambridge Antibody Technology in 2006 and culminating in its acquisition of US biotech firm, Medimmune in April 2007 for £15bn.

Pharmaceutical 40

Pharmaceutical Manufacturing Biopharma Medicine 40